RESET

The RESET project represents a bidirectional collaboration between InterMed, a dynamic representative of the industrial sector in Greece, and a unique research institute (ICB/NHRF) operating at the interface of chemistry and biology. The main focus of RESET is, on one hand, the optimization of bio-inspired small molecules that directly target the proteasome (structural activators), developed at ICB/NHRF, and, on the other hand, their application by InterMed, both in the short term as anti-aging ingredients in innovative dermocosmetics and in the long term as potential therapeutics for Alzheimer’s disease (AD).

The short-term objective of RESET is the incorporation of the most effective proteasome structural activator into model dermocosmetic formulations and the preparation of a technical dossier for cosmetic ingredients by InterMed. A market study will be conducted to explore the commercial potential of the new dermocosmetics and their integration into the company’s existing successful product lines.

The long-term objective is the utilization of the optimized proteasome structural activators emerging from preclinical studies in cellular and organismal models of neurodegeneration, by InterMed, as potential drugs for the prevention or treatment of age-related neurodegenerative disorders linked to proteasome dysfunction, such as Alzheimer’s disease.